Industry | Biotechnology |
---|---|
Founded | 1996 |
Founder | Dr. Herbert Stadler |
Headquarters | , Germany |
Key people | Dr. Herbert Stadler (Founder & President) Dr. Mike Rothe (CEO) |
Number of employees | ~50 |
Website | www.iba-lifesciences.com |
IBA Lifesciences is a biotechnology company providing products and custom specific services for life science applications in academia and industry worldwide. [1] IBA focusses on two business segments: cell selection and protein purification. [2]
The company is the original manufacturer and supplier of the Strep-tag/Strep-Tactin technology, an affinity chromatography system developed for protein purification. [3] The method is based on one of the strongest non-covalent interactions in nature, which is the interaction of biotin to streptavidin. An intrinsic binding affinity of the Strep-tag towards Strep-Tactin results in a highly specific interaction, which enables the isolation and purification of sensitive proteins in a native state as wells as intact protein complexes, respectively. [4] [5] The technology was patented by the Max Planck Society (former “Garching Innovations”) and later assigned to IBA. [6] [7] Recently, the method was further developed to be used for cell selection from whole blood or other single cell suspensions. [8]
IBA has developed an affinity chromatography system for non-magnetic isolation of peripheral blood mononuclear cells, T cells, B cells and other cells of interest. This technology is known as Fab-TACS (Traceless Affinity Cell Selection) and is based on Strep-tagged Fab fragments, which reversibly capture and release the target cells. This delivers label-free, non-activated cells suitable for immunologic or cell biological assays. The technology can be used with manual gravity flow columns as well as with the automated cell selection device FABian. [9] Isolated and purified cells are being deployed for basic research as well as diagnostic applications. [10] [11] The Streptamers for cell expansion enable the controlled stimulation of T cells. They consist of non-magnetic soluble protein complexes generated by multimerization of αCD3- and αCD28 Fab-Streps with a Strep-Tactin multimer. The reversible reagents can be easily removed from the cells by the addition of biotin. This allows to regulate the extent of stimulation precisely and to study functional and label-free activated T cells.
The company exhibits a wide range of tools related to recombinant protein purification consisting of expression vectors, affinity purification and detection reagents based on its Strep-tag/Strep-Tactin system. [12] [13] [14] [15] [16]
This can be used for i.e. drug screening, diagnostic assays, immobilization and interaction studies. Due to its small size and biochemically almost inert character, the Strep-tag does not influence protein folding, secretion and function. [17] [18]
The latest generation of the system is called Strep-Tactin XT. In combination with the Twin Strep-tag it binds the recombinant protein of interest with an extremely high affinity. This results in improved batch purification runs, higher yields of the expressed recombinant protein and a versatile approach for the immobilization on solid surfaces like beads, slides/arrays or microplates.
1996 - Institut für Bioanalytik GmbH was founded by Herbert Stadler, IBA introduces Strep-tag products
1998 - Acquisition of NAPS Göttingen GmbH (Nucleic Acid Products Supply)
1999 - Biologics joint venture with GBF Braunschweig [19]
2001 - Institut für Bioanalytik GmbH was renamed to IBA GmbH
2003 - IBA introduces Streptamer cell isolation technology
2004 - Operations segmented into Protein, Gene and Cell TAGnology business units
2007 - IBA introduces StarGate cloning system
2008 - Innovation Award for StarGate [20]
2010 - IBA introduces Fab-Streptamer technology
2011 - Innovation Award for Streptamer cell isolation technology [21]
2012 - IBA introduces Fab-TACS (Formerly known as T-CATCH) column based cell purification
2014 - IBA earned its ISO 9001:2008 certification for Quality Management Standard, [22] IBA introduces Strep-Tactin XT products
2015 - 6th foreign Trade Award of Lower Saxony (Germany), [23] IBA launches MEXi mammalian expression system
2016 - IBA introduces cell selection device FABian [24]
In 2011 IBA was granted multiple local innovation awards, e.g. for its Streptamer technology, which allows reversible isolation and staining of antigen-specific T cells. [25] [26] Additionally, a diagnostic test developed by IBA and Fassisi for veterinary diseases was chosen as one of the top five innovations by the county of Göttingen in 2015. [27] Furthermore, the company honors young scientists and participated in research consortia as well. [28] [29] [30]
IBA Lifesciences is a limited liability company (referred to as GmbH in Germany). The officers of the company are Dr. Herbert Stadler (Founder and President), Dr. Mike Rothe (CEO) and Dr. Joachim Bertram (CSO). Headquartered in Göttingen, Germany with locations in Leipzig, Munich (both Germany) and Saint Louis (United States).
A polyhistidine-tag, best known by the trademarked name His-tag, is an amino acid motif in proteins that typically consists of at least six histidine (His) residues, often at the N- or C-terminus of the protein. It is also known as a hexa histidine-tag, 6xHis-tag, or His6 tag. The tag was invented by Roche, although the use of histidines and its vectors are distributed by Qiagen. Various purification kits for histidine-tagged proteins are commercially available from multiple companies.
Protein purification is a series of processes intended to isolate one or a few proteins from a complex mixture, usually cells, tissues or whole organisms. Protein purification is vital for the specification of the function, structure and interactions of the protein of interest. The purification process may separate the protein and non-protein parts of the mixture, and finally separate the desired protein from all other proteins. Ideally, to study a protein of interest, it must be separated from other components of the cell so that contaminants will not interfere in the examination of the protein of interest's structure and function. Separation of one protein from all others is typically the most laborious aspect of protein purification. Separation steps usually exploit differences in protein size, physico-chemical properties, binding affinity and biological activity. The pure result may be termed protein isolate.
In biochemistry, biotinylation is the process of covalently attaching biotin to a protein, nucleic acid or other molecule. Biotinylation is rapid, specific and is unlikely to disturb the natural function of the molecule due to the small size of biotin. Biotin binds to streptavidin and avidin with an extremely high affinity, fast on-rate, and high specificity, and these interactions are exploited in many areas of biotechnology to isolate biotinylated molecules of interest. Biotin-binding to streptavidin and avidin is resistant to extremes of heat, pH and proteolysis, making capture of biotinylated molecules possible in a wide variety of environments. Also, multiple biotin molecules can be conjugated to a protein of interest, which allows binding of multiple streptavidin, avidin or neutravidin protein molecules and increases the sensitivity of detection of the protein of interest. There is a large number of biotinylation reagents available that exploit the wide range of possible labelling methods. Due to the strong affinity between biotin and streptavidin, the purification of biotinylated proteins has been a widely used approach to identify protein-protein interactions and post-translational events such as ubiquitylation in molecular biology.
Affinity chromatography is a method of separating a biomolecule from a mixture, based on a highly specific macromolecular binding interaction between the biomolecule and another substance. The specific type of binding interaction depends on the biomolecule of interest; antigen and antibody, enzyme and substrate, receptor and ligand, or protein and nucleic acid binding interactions are frequently exploited for isolation of various biomolecules. Affinity chromatography is useful for its high selectivity and resolution of separation, compared to other chromatographic methods.
Streptavidin is a 52 kDa protein (tetramer) purified from the bacterium Streptomyces avidinii. Streptavidin homo-tetramers have an extraordinarily high affinity for biotin. With a dissociation constant (Kd) on the order of ≈10−14 mol/L, the binding of biotin to streptavidin is one of the strongest non-covalent interactions known in nature. Streptavidin is used extensively in molecular biology and bionanotechnology due to the streptavidin-biotin complex's resistance to organic solvents, denaturants, detergents, proteolytic enzymes, and extremes of temperature and pH.
A tetrameric protein is a protein with a quaternary structure of four subunits (tetrameric). Homotetramers have four identical subunits, and heterotetramers are complexes of different subunits. A tetramer can be assembled as dimer of dimers with two homodimer subunits, or two heterodimer subunits.
Protein tags are peptide sequences genetically grafted onto a recombinant protein. Tags are attached to proteins for various purposes. They can be added to either end of the target protein, so they are either C-terminus or N-terminus specific or are both C-terminus and N-terminus specific. Some tags are also inserted at sites within the protein of interest; they are known as internal tags.
FLAG-tag, or FLAG octapeptide, or FLAG epitope, is a peptide protein tag that can be added to a protein using recombinant DNA technology, having the sequence DYKDDDDK. It is one of the most specific tags and it is an artificial antigen to which specific, high affinity monoclonal antibodies have been developed and hence can be used for protein purification by affinity chromatography and also can be used for locating proteins within living cells. FLAG-tag has been used to separate recombinant, overexpressed protein from wild-type protein expressed by the host organism. FLAG-tag can also be used in the isolation of protein complexes with multiple subunits, because FLAG-tag's mild purification procedure tends not to disrupt such complexes. FLAG-tag-based purification has been used to obtain proteins of sufficient purity and quality to carry out 3D structure determination by x-ray crystallography.
Protein A is a 42 kDa surface protein originally found in the cell wall of the bacteria Staphylococcus aureus. It is encoded by the spa gene and its regulation is controlled by DNA topology, cellular osmolarity, and a two-component system called ArlS-ArlR. It has found use in biochemical research because of its ability to bind immunoglobulins. It is composed of five homologous Ig-binding domains that fold into a three-helix bundle. Each domain is able to bind proteins from many mammalian species, most notably IgGs. It binds the heavy chain within the Fc region of most immunoglobulins and also within the Fab region in the case of the human VH3 family. Through these interactions in serum, where IgG molecules are bound in the wrong orientation, the bacteria disrupts opsonization and phagocytosis.
Fusion proteins or chimeric (kī-ˈmir-ik) proteins are proteins created through the joining of two or more genes that originally coded for separate proteins. Translation of this fusion gene results in a single or multiple polypeptides with functional properties derived from each of the original proteins. Recombinant fusion proteins are created artificially by recombinant DNA technology for use in biological research or therapeutics. Chimeric or chimera usually designate hybrid proteins made of polypeptides having different functions or physico-chemical patterns. Chimeric mutant proteins occur naturally when a complex mutation, such as a chromosomal translocation, tandem duplication, or retrotransposition creates a novel coding sequence containing parts of the coding sequences from two different genes. Naturally occurring fusion proteins are commonly found in cancer cells, where they may function as oncoproteins. The bcr-abl fusion protein is a well-known example of an oncogenic fusion protein, and is considered to be the primary oncogenic driver of chronic myelogenous leukemia.
Human influenza hemagglutinin (HA) is a surface glycoprotein required for the infectivity of the human influenza virus. The HA-tag is derived from the HA-molecule corresponding to amino acids 98-106. HA-tag has been extensively used as a general epitope tag in expression vectors. Many recombinant proteins have been engineered to express the HA-tag, which does not generally appear to interfere with the bioactivity or the biodistribution of the recombinant protein. This tag facilitates the detection, isolation and purification of the protein of interest.
The Strep-tag system is a method which allows the purification and detection of proteins by affinity chromatography. The Strep-tag II is a synthetic peptide consisting of eight amino acids (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys). This peptide sequence exhibits intrinsic affinity towards Strep-Tactin, a specifically engineered streptavidin, and can be N- or C- terminally fused to recombinant proteins. By exploiting the highly specific interaction, Strep-tagged proteins can be isolated in one step from crude cell lysates. Because the Strep-tag elutes under gentle, physiological conditions, it is especially suited for the generation of functional proteins.
Strep Tamer is a technology which allows the reversible isolation and staining of antigen-specific T-cells. This technology combines a current T-cell isolation method with the Strep-Tag technology. In principle, the T-cells are separated by establishing a specific interaction between the T-cell of interest and a molecule, that is conjugated to a marker which enables the isolation. The reversibility of this interaction and the low temperatures at which it is performed allow for the isolation and characterization of functional T-cells. Because T-cells remain phenotypically and functionally indistinguishable from untreated cells, this method offers modern strategies in clinical and basic T-cell research.
The Streptavidin-Binding Peptide (SBP)-Tag is a 38-amino acid sequence that may be engineered into recombinant proteins. Recombinant proteins containing the SBP-Tag bind to streptavidin and this property may be utilized in specific purification, detection or immobilization strategies.
Synthetic antibodies are affinity reagents generated entirely in vitro, thus completely eliminating animals from the production process. Synthetic antibodies include recombinant antibodies, nucleic acid aptamers and non-immunoglobulin protein scaffolds. As a consequence of their in vitro manufacturing method the antigen recognition site of synthetic antibodies can be engineered to any desired target and may extend beyond the typical immune repertoire offered by natural antibodies. Synthetic antibodies are being developed for use in research, diagnostic and therapeutic applications. Synthetic antibodies can be used in all applications where traditional monoclonal or polyclonal antibodies are used and offer many inherent advantages over animal-derived antibodies, including comparatively low production costs, reagent reproducibility and increased affinity, specificity and stability across a range of experimental conditions.
FlAsH-EDT2 is an organoarsenic compound with molecular formula C24H18As2O5S4. Its structure is based around a fluorescein core with two 1,3,2-dithiarsolane substituents. It is used in bioanalytical research as a fluorescent label for visualising proteins in living cells. FlAsH-EDT2 is an abbreviation for fluorescin arsenical hairpin binder-ethanedithiol, and is a pale yellow or pinkish fluorogenic solid. It has a semi-structural formula (C2H4AsS2)2-(C13H5O3)-C6H4COOH, representing the dithiarsolane substituents bound to the hydroxyxanthone core, attached to an o-substituted molecule of benzoic acid.
Affimer molecules are small proteins that bind to target proteins with affinity in the nanomolar range. These engineered non-antibody binding proteins are designed to mimic the molecular recognition characteristics of monoclonal antibodies in different applications. These affinity reagents have been optimized to increase their stability, make them tolerant to a range of temperatures and pH, reduce their size, and to increase their expression in E.coli and mammalian cells.
The NE-tag is a synthetic peptide tag designed as an epitope tag for detection, quantification and purification of recombinant protein. This patented peptide sequence is composed of eighteen hydrophilic amino acids. This short peptide does not adopt any significant homology to any existing proteins found in nature. This synthetic NE peptide adopts random coil conformation and showing strong immunogenicity. This is advantageous to offer stringent specificity to the NE-tagged proteins, which are readily to be detected, quantitated, and purified.
Mathias Uhlén is a Swedish scientist and Professor of Microbiology at Royal Institute of Technology (KTH), Stockholm. After a post-doc period at the EMBL in Heidelberg, Germany, he became professor in microbiology at KTH in 1988. His research is focused on protein science, antibody engineering and precision medicine and range from basic research in human and microbial biology to more applied research, including clinical applications. He is member of several academies and societies, including Royal Swedish Academy of Science (KVA), National Academy of Engineering (NAE) and the Swedish Academy of Engineering Science (IVA). Dr Uhlen was the Founding Director of the national infrastructure Science for Life Laboratory (SciLifeLab) from 2010 to 2015.
Recombinant antibodies are antibody fragments produced by using recombinant antibody coding genes. They mostly consist of a heavy and light chain of the variable region of immunoglobulin. Recombinant antibodies have many advantages in both medical and research applications, which make them a popular subject of exploration and new production against specific targets. The most commonly used form is the single chain variable fragment (scFv), which has shown the most promising traits exploitable in human medicine and research. In contrast to monoclonal antibodies produced by hybridoma technology, which may lose the capacity to produce the desired antibody over time or the antibody may undergo unwanted changes, which affect its functionality, recombinant antibodies produced in phage display maintain high standard of specificity and low immunogenicity.